These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8054006)

  • 1. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.
    Legha SS; Buzaid AC
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):27-32. PubMed ID: 8054006
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA; Pierce WC; Belldegrun A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract]   [Full Text] [Related]  

  • 3. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
    Buzaid AC; Legha SS
    Semin Oncol; 1994 Dec; 21(6 Suppl 14):23-8. PubMed ID: 7992096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What can we learn from phase II adjuvant trials in melanoma?
    Keilholz U; Suciu S; Eggermont AM
    Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
    [No Abstract]   [Full Text] [Related]  

  • 7. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by alpha-interferon and dacarbazine--a preliminary report.
    Merimsky O; Inbar M; Shiloni E; Ron I; Chaitchik S
    Mol Biother; 1990 Dec; 2(4):208-10. PubMed ID: 2288720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
    Legha SS
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
    Legha SS; Ring S; Eton O; Bedikian A; Plager C; Papadopoulos N
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approaches to the systemic treatment of melanoma.
    Chowdhury S; Vaughan MM; Gore ME
    Cancer Treat Rev; 1999 Oct; 25(5):259-70. PubMed ID: 10544070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant application of interferons.
    el Kassas H; Kirkwood JM
    Semin Oncol; 1996 Dec; 23(6):737-43. PubMed ID: 8970596
    [No Abstract]   [Full Text] [Related]  

  • 13. [Chemotherapy of malignant melanoma].
    Avril MF
    Ann Dermatol Venereol; 1988; 115(9):959-68. PubMed ID: 2464963
    [No Abstract]   [Full Text] [Related]  

  • 14. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
    Thompson JA; Gold PJ; Fefer A
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Systemic therapy of metastatic malignant melanoma].
    Stahel RA; Martz G
    Schweiz Rundsch Med Prax; 1988 Apr; 77(17):459-62. PubMed ID: 3259710
    [No Abstract]   [Full Text] [Related]  

  • 16. Melanoma: therapeutic options with recombinant interferons.
    Kirkwood JM; Ernstoff M
    Semin Oncol; 1985 Dec; 12(4 Suppl 5):7-12. PubMed ID: 2417333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination of dacarbazine, cisplatin and interferon alpha in the treatment of metastatic melanoma].
    Tessier MH; Mansat E; Legoux B; Litoux P; Dreno B
    Ann Dermatol Venereol; 1996; 123(9):538-42. PubMed ID: 9615103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin and dacarbazine with or without subcutaneous interleukin-2 and interferon alfa-2b in advanced melanoma outpatients.
    Koduri J; Baumann MA
    J Clin Oncol; 2002 Aug; 20(16):3560; author reply 3560-1. PubMed ID: 12177119
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined chemotherapy with or without interferon alpha N1 (IFN) for advanced malignant melanoma--a randomized pilot phase III study.
    Gorbonova VA; Egorov GN; Perevodchikova NI; Orel NF
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():310-4. PubMed ID: 10939991
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
    Fierro MT; Bertero M; Novelli M; Appino A; Doveil GC; Colonna S; Bernengo MG
    Melanoma Res; 1993 Apr; 3(2):127-31. PubMed ID: 8518551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.